- Home
- GALT vs KOD Comparison
GALT vs KOD Comparison
Compare GALT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- KOD
- Stock Information
- Founded
- GALT 2000
- KOD 2009
- Country
- GALT United States
- KOD United States
- Employees
- GALT N/A
- KOD N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GALT Health Care
- KOD Health Care
- Exchange
- GALT Nasdaq
- KOD Nasdaq
- Market Cap
- GALT 232.3M
- KOD 198.4M
- IPO Year
- GALT N/A
- KOD 2018
- Fundamental
- Price
- GALT $3.57
- KOD $10.57
- Analyst Decision
- GALT Strong Buy
- KOD Hold
- Analyst Count
- GALT 3
- KOD 4
- Target Price
- GALT $6.00
- KOD $11.25
- AVG Volume (30 Days)
- GALT 299.1K
- KOD 715.4K
- Earning Date
- GALT 08-14-2025
- KOD 08-13-2025
- Dividend Yield
- GALT N/A
- KOD N/A
- EPS Growth
- GALT N/A
- KOD N/A
- EPS
- GALT N/A
- KOD N/A
- Revenue
- GALT N/A
- KOD N/A
- Revenue This Year
- GALT N/A
- KOD N/A
- Revenue Next Year
- GALT N/A
- KOD N/A
- P/E Ratio
- GALT N/A
- KOD N/A
- Revenue Growth
- GALT N/A
- KOD N/A
- 52 Week Low
- GALT $0.73
- KOD $1.92
- 52 Week High
- GALT $4.41
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- GALT 58.06
- KOD 77.63
- Support Level
- GALT $3.55
- KOD $7.69
- Resistance Level
- GALT $3.90
- KOD $8.45
- Average True Range (ATR)
- GALT 0.32
- KOD 0.83
- MACD
- GALT -0.04
- KOD 0.17
- Stochastic Oscillator
- GALT 41.67
- KOD 85.66
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.